Double Blind Randomized Trial of Saline vs Pentaspan for Resuscitation After Cardiac Surgery
A Randomized Trial of Synthetic vs Normal Saline for the Flow-based Algorithmic Hemodynamic Resuscitation of Patients Post-cardiac Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1A1
- Royal Victoria Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- status post cardiac surgery
- pulmonary artery occlusion catheter in place
- informed consent
- morning case (must be out of OR by 2:00 PM
Exclusion Criteria:
- excessive bleeding (> 200 cc/hr)
- intraaortic balloon pump
- refusal by treating team
- emergency cases
- patients with known adverse reactions to starch solutions
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: 1 colloid
Boluses of fluids are a pentastarch (up to 1000 ml)
|
When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
|
|
Active Comparator: 2. Crytalloid
Boluses are given as normal saline
|
When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Use of catecholamines at 8:00 the morning after surgery
Time Frame: first post operative day
|
first post operative day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Total use of catecholamines
Time Frame: Time in ICU
|
Time in ICU
|
|
Time in the ICU
Time Frame: Time in ICU
|
Time in ICU
|
|
Post-operative complications
Time Frame: Hospital stay or 28 days
|
Hospital stay or 28 days
|
|
Bleeding
Time Frame: Hospital stay or 28 days
|
Hospital stay or 28 days
|
|
Renal failure
Time Frame: Hospital stay or 28 days
|
Hospital stay or 28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: sheldon magder, md, McGill University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BMA-04-016
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.